Literature DB >> 11192295

CD8+ cell lines isolated from HIV-1-infected children have potent soluble HIV-1 inhibitory activity that differs from beta-chemokines.

A Mosoian1, A Teixeira, E Caron, J Piwoz, M E Klotman.   

Abstract

CD8+ cells from human immunodeficiency virus type 1 (HIV-1) infected individuals have been shown to suppress HIV-1 replication both through a major histocompatibility complex (MHC)-restricted cytolytic pathway as well as through a noncytolytic pathway mediated through soluble factors. To characterize this soluble activity and its potential role in disease progression further, we studied the HIV-1 inhibition by supernatants derived from herpesvirus saimiri-transformed CD8+ cells isolated from infected children. Three of the six CD8+ cell lines derived had a phenotype consistent with an unusual natural killer (NK) cells phenotype with low CD3, high CD56, and low CD16. Supernatants from some of the cell lines derived from children with rapid progression as well as long-term nonprogressors exhibited broad HIV-1-inhibitory activity in primary CD4+ cells as well as in primary macrophages. In contrast to a cocktail of beta-chemokines, the supernatants inhibited T-tropic as well as M-tropic viruses, efficiently inhibited infection in primary macrophages, and inhibited HIV-1 activation in the chronically infected U1 cell line. The HIV-1-inhibitory activity was heat stable and active over a broad pH range. Fractionation of the supernatant by size and ion exchange chromatography demonstrated activity in the complete absence of RANTES as well as interferons-alpha, beta, and gamma and in a size range of less than 10 kD and greater than 3 kD. CD8+ cell supernatants contain additional unidentified factors that have anti-HIV activity to account for this broad phenomenon.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11192295     DOI: 10.1089/vim.2000.13.481

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  6 in total

1.  Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages.

Authors:  Arevik Mosoian; Avelino Teixeira; Anthony A High; Robert E Christian; Donald F Hunt; Jeffrey Shabanowitz; Xinyan Liu; Mary Klotman
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 2.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

3.  Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction.

Authors:  Arevik Mosoian; Avelino Teixeira; Colin S Burns; Leif E Sander; G Luca Gusella; Cijiang He; J Magarian Blander; Paul Klotman; Mary E Klotman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

4.  A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation.

Authors:  Theresa Li-Yun Chang; Arevik Mosoian; Richard Pine; Mary E Klotman; John P Moore
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27.

Authors:  J Mohamad Fakruddin; Richard A Lempicki; Robert J Gorelick; Jun Yang; Joseph W Adelsberger; Alfonso J Garcia-Pineres; Ligia A Pinto; H Clifford Lane; Tomozumi Imamichi
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

6.  CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition.

Authors:  Theresa Li-Yun Chang; Fleur François; Arevik Mosoian; Mary E Klotman
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.